Gastromedic s.r.o.
- Address
- Narodnich Hrdinu 183, Pardubicky, 530 03 Pardubice, Czechia
Inflammatory Bowel Disease Research
The research focuses on Inflammatory Bowel Disease. Trials are enrolling participants with Crohn's disease. A parallel effort studies patients with ulcerative colitis. The goal is to test new oral agents for inducing remission and maintaining disease control.
- Oral TAK-279 for moderate to severe Crohn's disease
- Oral TAK-279 for moderate to severe ulcerative colitis
- Long‑term safety of zasocitinib in Crohn's disease and ulcerative colitis
- Icotrokinra induction and maintenance in ulcerative colitis
- Icotrokinra efficacy in Crohn's disease
Gastromedic s.r.o. in Pardubice is coordinating these studies, contributing to advances in immune system disease therapeutics.
GERD and Erosive Esophagitis Studies
The site investigates gastroesophageal reflux disease and its complication erosive esophagitis. Research compares a novel agent with standard therapy to improve healing. Long‑term maintenance of healed esophagus is also evaluated.
- Linaprazan glurate vs lansoprazole for induction of healing in EE
- High‑dose linaprazan glurate vs lansoprazole for maintenance of healed EE
- Assessment of endoscopic response after 4 weeks of treatment
Gastromedic s.r.o. supports these digestive system disease trials, aiming to provide better options for patients with reflux‑related conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gastromedic s.r.o.
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease | Janssen Cilag International | Phase IV | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Zasocitinib | 3 | Unknown | 2024-09-04 | 2025-08-27 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.